Evaluation and Management of the Patient with Pulmonary Arterial Hypertension

@article{Rubin2005EvaluationAM,
  title={Evaluation and Management of the Patient with Pulmonary Arterial Hypertension},
  author={Lewis J. Rubin and David B. Badesch},
  journal={Annals of Internal Medicine},
  year={2005},
  volume={143},
  pages={282-292}
}
Until recently, management of pulmonary arterial hypertension (PAH) was generally ineffective in alleviating symptoms or improving survival. However, the past decade has witnessed remarkable advances in our understanding of the pathogenesis of PAH, advances that have led to the development of disease-specific treatments. Despite these achievements, PAH remains a challenging condition to diagnose and manage. This article reviews recent developments in the diagnosis and management of PAH in the… Expand
Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications
TLDR
Although new advanced therapies hold promise in PAH secondary to CHD, long-term data are clearly needed and advanced therapies should be considered when other causes of functional limitation, such as iron deficiency, have been first addressed. Expand
Essential echocardiographic evaluation in patients with suspected pulmonary hypertension: an overview for the practicing physician
TLDR
The most important objective measures that can be routinely employed, without added complexity, that will certainly enhance the interpretation and advance the understanding of the hemodynamic and mechanical abnormalities that PH exerts on the RV are highlighted. Expand
Syncope in adults with pulmonary arterial hypertension.
TLDR
Syncope in PAH is associated with worsening right heart function and is an independent predictor of a poor prognosis and is a significant predictor of mortality. Expand
[Seven years of experience in patients with pulmonary arterial hypertension in Ege University Hospital: diagnostic approach of a single center].
TLDR
The authors' practice shows that PAH is diagnosed late in the course of the disease in Turkey, and can be overcome with structured management in designated centers with multidisciplinary team-working in a shared care approach. Expand
Pulmonary arterial hypertension.
TLDR
The purpose of this review is to describe the current state of evidence for the diagnosis, prognosis, and treatment of the patient with PAH. Expand
non-parenteral Therapy for pulmonary Arterial Hypertension: A Review of Efficacy, Tolerability and Factors Related to Patient Adherence
TLDR
The aim of this review is to review the evidence for efficacy and safety of non-parenteral PAH therapies and to discuss treatment selection based on clinically meaningful differences among the approved therapies, such as the potential for serious drug-drug interactions, convenience of dosing schedules, and rates of limiting side effects. Expand
Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries
TLDR
This chapter reviews those large-scale registries and conducts a detail comparison of clinical characteristics of IPAH between developed and developing countries. Expand
Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment.
TLDR
Responsibility for response to treatment can be measured by exercise capacity and pro-BNP, although certain aspects of validation for these outcome measures are lacking in PAH associated with connective tissue diseases. Expand
Pulmonary Arterial Hypertension of Congenital Heart Diseases: From Reversible Pulmonary Hypertension to Eisenmenger Syndrome
TLDR
There is still no cure for Eisenmenger syndrome, but the new vasodilators may be well tolerated and they improve the exercise capacity and hemodynamics without compromising the peripheral oxygen saturation. Expand
Evidence-based pharmacologic management of pulmonary arterial hypertension.
TLDR
Infusions of the prostacyclin analogues epoprostenol and treprostinil appear to be the treatment of choice for moderate to severe PAH, and agents with alternate routes of delivery such as inhaled iloprost may be advantageous in adjunctive roles. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Primary pulmonary hypertension: natural history and the importance of thrombosis.
TLDR
In more than half the patients undergoing autopsy the major histologic feature was thrombi without any evidence of plexiform lesions, and the two groups were similar with respect to their clinical and hemodynamic features and short survival. Expand
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
TLDR
A decreasing DLCO is an excellent predictor of the subsequent development of isolated PHT in limited scleroderma, and newer agents that are more effective in treating PHT may also be helpful in altering the natural history of this serious complication inlimited sclerodma. Expand
Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.
TLDR
Findings indicate that specific noninvasive studies are helpful in assessing the likelihood of normal or definitely elevated pulmonary artery pressures in patients with progressive systemic sclerosis, but patients with mild pulmonary hypertension are not likely to be identified by these nonin invasive studies. Expand
Prevalence of pulmonary hypertension in limited and diffuse scleroderma.
TLDR
Undiagnosed elevation of PAs is common in patients with scleroderma and noninvasive assessment of P as can be performed accurately in most patients independent of clinical signs of pulmonary hypertension. Expand
Primary pulmonary hypertension.
TLDR
For patients unresponsive during acute testing, continuous intravenous epoprostenol (prostacyclin, PGI2) improves haemodynamics and exercise tolerance, and prolongs survival in severe PPH (NYHA functional class III-IV). Expand
The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
TLDR
Sildenafil improves exercise capacity and symptoms, and decreases pulmonary artery pressures in patients with primary or secondary pulmonary hypertension of varied etiology, poorly controlled on conventional treatment. Expand
Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment.
TLDR
Investigation into the clinical features of systemic lupus erythematosus complicated with pulmonary hypertension and the efficacy of immunosuppressive treatment found CS +/- CYC was effective for PH associated with SLE to improve prognosis. Expand
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
TLDR
Results from a single-center, uncontrolled study suggest that long-term, continuously infused epoprostenol therapy can produce hemodynamic and symptomatic responses in patients with connective tissue disease who have severe pulmonary hypertension that is refractory to conventional medical therapy. Expand
Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
TLDR
In patients with severe primary or secondary pulmonary hypertension, inhalation of aerosolized iloprost, the stable analogue of prostacyclin, substantially decreases pulmonary artery pressure and resistance and increases cardiac output without a significant decrease in systemic artery Pressure and ventilation-perfusion mismatch. Expand
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
TLDR
Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow- up periods. Expand
...
1
2
3
4
5
...